Posted by The goal of this research initiative was to explore the utilization of a microparticle antibiotic delivery system, which could provide localized and sustained antibiotic dosing. The outcome of this work demonstrates the feasibility of providing efficient localized delivery of antibiotics to manage infection using both preclinical in vitro and in vivo cistic fibrosis infection models. The studies outlined in this manuscript demonstrate the proof-of-concept and unique capacity of polymerized cyclodextrin microparticles to provide site-directed management of pulmonary infections.
Cyclodextrin polymer disks (8 mm) were prepared by further crosslinking of commercial epichlorohydrin-CD prepolymer with hexamethylene diisocyanate, then loaded with antibiotics (vancomycin, gentamicin, piperacillin, or tazobactam).
Cyclodextrin polymer microparticles were prepared by further crosslinking of commercial epichlorohydrin-CD prepolymer with ethylene glycol diglyceryl ether in suspension to get tiny beads (100 nm).
Cyclodextrin microparticles loaded with either piperacillin or tazobactam demonstrated an initial burst of drug, with sustained release for up to 8 days.
Polymerized cyclodextrin microparticles have the potential to provide a unique drug delivery system that can be optimized to manage the delivery of antibiotics. These studies demonstrate the proof-of-concept for pCD microparticle antibiotic delivery to treat pulmonary infections.
Reference:
Tracey L. Bonfield, Sean T. Zuckerman, Morgan T. Sutton, Julius N. Korley, Horst A. von Recum, Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections. Journal of Biomedical Materials Research, Part A. First published: 21 February 2024 https://doi.org/10.1002/jbm.a.37680